Skin Peptide Research Glossary for Canadian Labs

Why Northern Compound needed a skin peptide glossary#

Skin peptide content has a vocabulary problem. The same page can mention collagen, barrier repair, wound healing, anti-aging, melanogenesis, antimicrobial activity, inflammation, and regeneration as if all of those words point to the same evidence layer. They do not. A fibroblast matrix signal is not a barrier outcome. A melanin-content assay is not a tanning recommendation. A keratinocyte migration result is not wound-care guidance. A cytokine shift is not proof of clinical benefit.

That problem gets sharper in Canadian research-material sourcing. Skin is one of the easiest categories for RUO copy to slide into consumer implication because readers already recognize cosmetic and dermatology language. A product page may mention GHK-Cu, LL-37, KPV, Melanotan-1, or Melanotan-2 beside language that sounds useful but is too vague for a research file. Northern Compound should force those terms back into assays, controls, and documentation.

This glossary is a stable reference for the skin archive: where to buy skin peptides in Canada, best skin peptides Canada, skin barrier peptides, skin microbiome peptides, melanosome transfer peptides, and dermal fibroblast senescence peptides. It translates common terms into research questions. It does not turn them into usage instructions.

The practical rule is simple: if a skin term cannot be connected to a defined model, assay, time point, comparator, and interpretation limit, it should not drive sourcing or claims. “Skin support” is not a research endpoint. “Collagen biology in dermal fibroblasts after a defined exposure window” is closer. “MC1R-linked melanogenesis in a melanocyte model with melanin quantification and receptor-context controls” is closer still. The specificity is the point.

Quick answer: how to use this glossary#

Use this article as a pre-protocol and pre-supplier-page vocabulary check. Before a skin peptide article, product page, or outreach asset uses a term, ask five questions:

1. Which skin layer or cell type is being discussed? Epidermis, dermis, keratinocytes, melanocytes, fibroblasts, endothelial cells, immune cells, sebocytes, and hair-follicle cells are not interchangeable.
2. Which endpoint is measured? Collagen expression, elastin context, keratinocyte migration, tight-junction protein expression, TEER, cytokine release, melanin content, tyrosinase activity, microbial burden, angiogenesis markers, and histology all answer different questions.
3. Which compound is actually relevant? GHK-Cu belongs in matrix and fibroblast contexts. LL-37 belongs in cathelicidin, host-defence, barrier, and epithelial-immune contexts. KPV belongs in inflammatory-tone or melanocortin-adjacent epithelial models. Melanotan-1 and Melanotan-2 belong in melanocortin and pigmentation biology, not generic skin-benefit copy.
4. What does the supplier file prove? A lot-matched COA, HPLC purity, mass confirmation, identity language, batch number, fill amount, storage guidance, and RUO labelling prove material documentation. They do not prove a skin outcome.
5. What claim is being avoided? No article should turn a research endpoint into human cosmetic advice, tanning advice, wound-treatment guidance, disease treatment, or administration instruction.

Core skin peptide terms#

Skin peptide#

“Skin peptide” is not a precise scientific class. In search and supplier language, it usually means a peptide or peptide-adjacent compound discussed around dermal matrix biology, wound-context models, pigmentation, epithelial immunity, barrier function, microbiome interaction, inflammation, hydration models, or visible-skin marketing. That range is too broad to be useful unless the article narrows it.

For Northern Compound, the phrase should be an archive label, not a benefit claim. GHK-Cu may be relevant when the question involves extracellular matrix or fibroblast behaviour. LL-37 may be relevant when the model involves cathelicidin signalling, antimicrobial context, epithelial immunity, or barrier response. KPV may be relevant when the question is inflammatory tone or melanocortin-adjacent signalling. Melanotan-1 and Melanotan-2 may be relevant when the question is melanocortin receptor biology or pigmentation models.

The mistake is using “skin peptide” as if the skin category itself proves relevance. A better sentence is: “This material is being discussed in a skin research context because the protocol measures X endpoint in Y skin model.” That sentence forces the evidence layer into the open.

Research-use-only#

Research-use-only, or RUO, means the material and content are framed for laboratory research rather than diagnosis, treatment, prevention, cure, personal use, cosmetic use, or human/animal administration outside approved protocols. RUO language is not a magic shield. Health Canada has warned consumers about unauthorized peptide products sold online and about products promoted for anti-aging, injury recovery, weight loss, performance, sleep, focus, or wellness in consumer contexts (Health Canada safety alert).

For skin content, RUO boundaries matter because the category is full of visible-outcome language. Northern Compound articles should avoid dosing, injection, reconstitution instructions for personal use, topical-use directions, cosmetic routines, tanning instructions, wound-care advice, disease treatment claims, cure language, fake testimonials, and body-transformation copy. The sourcing question is documentation-first: identity, purity, mass confirmation, storage, COA match, and compliant claim boundaries. The research-use-only compliance checklist covers that layer directly.

Cosmetic peptide#

“Cosmetic peptide” is common market language, but it is not a clean RUO category. It may refer to ingredients used in topical formulations, signalling peptides discussed in skin-care marketing, copper-peptide complexes, carrier peptides, or branded sequences. A research article should not borrow cosmetic language unless it is clearly describing formulation science, ingredient taxonomy, or non-clinical assay context.

This distinction matters for GHK-Cu. A product listed as GHK-Cu for research use should not be treated as a finished cosmetic ingredient or topical product. Conversely, a cosmetic ingredient page does not prove that a lyophilized RUO material is appropriate for a lab protocol. The GHK-Cu cosmetic-grade guide handles that distinction in more detail.

Endpoint-first sourcing#

Endpoint-first sourcing means choosing the material after defining the research endpoint, not before. It is the opposite of starting with a product list and inventing a broad “skin” rationale afterward.

A strong skin research file names the endpoint family: matrix remodelling, keratinocyte migration, barrier integrity, melanogenesis, epithelial immunity, cytokine response, microbiome interaction, vascular response, senescence, or hair-follicle cycling. It then names the model, assay, controls, and material requirements. Only after that does the file inspect supplier documentation. The research peptide supplier scorecard and peptide COA verification checklist are practical companions to this glossary.

Compound terms in the skin archive#

GHK-Cu#

GHK-Cu is a copper-binding tripeptide usually discussed around dermal matrix biology, wound-context remodelling, fibroblast behaviour, collagen, elastin-adjacent markers, glycosaminoglycans, antioxidant context, and tissue-repair models. In Northern Compound skin content, GHK-Cu is the clearest live product reference when the endpoint is dermal matrix or fibroblast-centred.

Useful terms around GHK-Cu include extracellular matrix, collagen I/III, elastin, decorin, glycosaminoglycans, MMPs, TIMPs, fibroblast migration, wound-bed remodelling, oxidative stress, and senescence-associated secretory phenotype. Reviews discuss GHK-Cu in skin regeneration and tissue-remodelling contexts (Pickart et al., 2015; GHK anti-aging peptide review). Those sources provide mechanistic context. They do not justify cosmetic-result claims for an RUO supplier page.

A Canadian sourcing file should identify the material precisely. “Copper peptide” is too vague. The file should record whether the material is GHK-Cu, free GHK, a copper salt mixture, a cosmetic ingredient, or another complex. It should include lot-specific purity and identity confirmation and avoid implying that the material is a skin-care product or wound-treatment product.

Internal context: GHK-Cu Canada guide, where to buy GHK-Cu in Canada, GHK-Cu vs LL-37, and dermal collagen peptides.

LL-37#

LL-37 is the active peptide form associated with human cathelicidin antimicrobial peptide biology. In skin research, it appears around host defence, keratinocyte behaviour, epithelial barrier context, microbial challenge, cytokine signalling, angiogenesis-adjacent wound models, and inflammatory skin biology. LL-37 belongs in skin content when the endpoint is immune-epithelial, antimicrobial, barrier, or wound-context signalling. It is not a generic beauty peptide.

Useful terms include cathelicidin, antimicrobial peptide, keratinocyte migration, tight-junction proteins, epithelial immunity, microbial burden, biofilm context, cytokines, chemotaxis, and barrier response. One keratinocyte study reported LL-37 effects on tight-junction protein expression and barrier-associated markers in normal human keratinocytes (PMC6742956). That is a research endpoint, not a consumer treatment claim.

LL-37 can be easy to overstate because antimicrobial and wound language sound clinically loaded. Northern Compound should keep the distinction sharp: antimicrobial activity in an assay is not infection treatment; keratinocyte migration is not wound-care advice; cytokine modulation is not disease management. The model decides the claim.

Internal context: LL-37 Canada guide, skin microbiome peptides, keratinocyte migration peptides, and cutaneous immune-surveillance peptides.

KPV#

KPV is a short tripeptide motif commonly discussed around melanocortin-adjacent anti-inflammatory signalling, cytokine context, epithelial models, and barrier-stress research. In Northern Compound skin content, KPV belongs when the question is inflammatory tone, epithelial cytokines, barrier stress, mast-cell-adjacent context, or melanocortin-related comparison work. It should not be treated as a collagen peptide or cosmetic default.

Useful KPV terms include cytokine response, NF-kB context, epithelial inflammation models, barrier stress, melanocortin signalling, macrophage/immune-cell context, keratinocyte response, and comparator design. The risk is directionality. “Anti-inflammatory” can become a therapeutic claim if the article does not specify the model and endpoint. Safer language says that KPV is discussed in inflammatory-tone models where cytokine panels or pathway markers are measured.

Internal context: KPV Canada guide, skin barrier peptides, mast-cell skin peptides, and vascular redness skin peptides.

Melanotan-1#

Melanotan-1 is an alpha-MSH analogue discussed around melanocortin receptor biology, especially MC1R-linked pigmentation models, eumelanin production, melanocyte signalling, photobiology, and UV-response research. In Northern Compound skin content, Melanotan-1 is the cleaner live product reference when the endpoint is MC1R-linked melanogenesis rather than broad receptor comparison.

Useful terms include alpha-MSH, MC1R, cAMP, MITF, tyrosinase, eumelanin, pheomelanin, melanocyte, melanosome, UV-response markers, and photobiology. MC1R is central to pigmentation biology, and melanocortin signalling is widely studied in melanocytes (MC1R melanocyte regulation). Those mechanisms support research questions. They do not support tanning instructions or claims about protection in people.

Internal context: Melanotan-1 Canada guide, where to buy Melanotan-1 in Canada, pigmentation and melanogenesis peptides, and Melanotan-1 vs Melanotan-2.

Melanotan-2#

Melanotan-2 is another melanocortin analogue, often discussed as broader and less skin-specific than Melanotan-1 in receptor-context conversations. In skin research, Melanotan-2 is most defensible when the protocol explicitly needs receptor-breadth comparison, melanocortin-system context, or a comparator for Melanotan-1.

The compliance risk is high because online demand often collapses Melanotan-2 into tanning or appearance language. Northern Compound should not do that. If Melanotan-2 appears in a skin article, the sentence should name the research layer: melanocortin receptor comparison, pigmentation model, melanocyte signalling, MC1R-adjacent interpretation, or receptor-selectivity discussion. It should not instruct readers on use.

Internal context: Melanotan-2 Canada guide, where to buy Melanotan-2 in Canada, melanosome transfer peptides, and Melanotan-1 vs Melanotan-2.

Cell and tissue glossary#

Keratinocyte#

Keratinocytes are the dominant cell type in the epidermis. They form much of the physical barrier, participate in immune signalling, produce cytokines and antimicrobial mediators, and coordinate with melanocytes, immune cells, and dermal signals. In skin peptide content, keratinocytes are relevant to barrier integrity, wound-edge migration, inflammatory response, tight junctions, differentiation, and host-defence models.

Keratinocyte language should be assay-specific. Does the protocol measure scratch closure, proliferation, differentiation markers, filaggrin, involucrin, claudins, cytokines, antimicrobial peptide expression, or TEER? A change in one keratinocyte marker does not prove barrier repair. A migration assay does not prove wound healing in an organism.

Fibroblast#

Dermal fibroblasts are cells in the dermis that produce and remodel extracellular matrix. They are central to collagen, elastin-adjacent context, glycosaminoglycans, wound-bed organization, matrix stiffness, senescence, and repair-biology models. GHK-Cu content often belongs here, but fibroblast biology is broader than any one compound.

Fibroblast endpoints can include collagen I/III expression, MMP/TIMP balance, proliferation, migration, senescence markers, cytokine secretion, oxidative-stress response, and matrix deposition. The interpretation depends on context. More collagen expression is not automatically better. Matrix remodelling can be adaptive, fibrotic, immature, or assay-specific. A serious article names the model and the direction of change without promising a visible outcome.

Melanocyte#

Melanocytes are pigment-producing cells that synthesize melanin and transfer melanosomes to keratinocytes. In skin peptide content, melanocytes are relevant to alpha-MSH, MC1R, cAMP, MITF, tyrosinase, eumelanin, pheomelanin, UV-response models, and melanosome transfer.

Melanocyte language should never become tanning advice. A melanogenesis assay may measure tyrosinase activity, melanin content, gene expression, cell viability, or melanosome transfer. Those data can support a mechanism. They do not tell a person to use a compound or prove a protective result.

Extracellular matrix#

The extracellular matrix, or ECM, is the structural and signalling environment around cells. In skin, it includes collagen, elastin, glycosaminoglycans, proteoglycans, fibronectin, laminins, and basement-membrane components. The ECM is central to dermal structure, wound healing, cell migration, stiffness, and tissue remodelling. Reviews of skin wound healing emphasize that ECM is not passive scaffolding; it actively shapes repair, inflammation, and remodelling (skin ECM review).

For peptide content, ECM terms should be tied to measured markers. “Supports matrix” is weak. Stronger language names collagen I, collagen III, elastin, decorin, MMP-1, MMP-9, TIMP-1, hyaluronic acid, fibronectin, or histological organization, then states the model and limits.

Basement membrane#

The basement membrane is a specialized ECM layer between epithelial cells and underlying connective tissue. In skin, it helps organize epidermal-dermal attachment, signalling, and barrier architecture. It is relevant when articles discuss epidermal integrity, wound re-epithelialization, laminins, collagen IV, or dermal-epidermal junction context.

A basement-membrane marker should not be used as a proxy for the entire skin barrier. It is one layer in a layered system. If a peptide article discusses basement-membrane biology, it should name whether the endpoint is protein expression, localization, tissue architecture, or functional barrier readout.

Stratum corneum#

The stratum corneum is the outermost layer of the epidermis. It includes corneocytes and lipid-rich layers that help manage barrier function, water loss, and environmental exposure. It appears in content around barrier integrity, ceramides, lamellar bodies, lipid organization, TEWL, and hydration models.

Peptide articles should be careful here because many peptide experiments occur in cells or animals, not in fully formed human stratum-corneum systems. If the model does not measure stratum-corneum structure or barrier function, do not claim stratum-corneum effects.

Endpoint glossary#

Collagen#

Collagen is a major structural protein family in skin, especially in the dermal ECM. Skin articles often mention collagen as if it is a single outcome. It is not. A study might measure collagen I mRNA, collagen III protein, hydroxyproline content, immunostaining, histological organization, or matrix stiffness. Those endpoints carry different meanings.

For GHK-Cu or matrix-remodelling content, collagen language should name the marker and model. “Increased collagen” is not enough. The article should say whether the signal came from fibroblasts, tissue, wound model, histology, gene expression, or protein assay, and whether matrix organization was measured. It should avoid translating collagen markers into visible anti-aging claims.

Elastin#

Elastin is an ECM protein associated with elasticity in tissues. In skin content, elastin language often appears near dermal structure, photoaging models, matrix remodelling, and fibroblast activity. It is easy to use elastin as shorthand for “firmer skin,” but that is not acceptable for RUO copy.

A stronger article asks whether elastin expression, elastase activity, elastic-fibre organization, or related markers were measured. If the study only measures fibroblast viability or collagen expression, elastin should not be implied.

Matrix metalloproteinases and TIMPs#

Matrix metalloproteinases, or MMPs, are enzymes involved in ECM degradation and remodelling. TIMPs are tissue inhibitors of metalloproteinases. Skin articles often discuss the balance between MMPs and TIMPs in wound healing, photoaging, inflammation, and matrix turnover.

The balance is context-dependent. Lower MMP activity is not always better; remodelling requires controlled matrix breakdown. Higher TIMP activity is not always better; excessive inhibition can alter normal turnover. Use MMP/TIMP language only when the assay measured the relevant enzymes or transcripts and the model supports interpretation.

Keratinocyte migration#

Keratinocyte migration is movement of epidermal cells, often studied in scratch assays, wound-edge models, or re-epithelialization contexts. It is relevant to LL-37 and epithelial-repair discussions, but it must be interpreted narrowly.

A scratch assay is not wound healing. It can be influenced by proliferation, cell density, media conditions, imaging timing, assay geometry, and cytotoxicity. A strong article calls it a migration or closure assay unless the model truly supports broader wound-context language.

Barrier integrity#

Barrier integrity refers to the ability of an epithelial or skin model to restrict unwanted movement of water, solutes, microbes, irritants, or inflammatory triggers. It may be measured through TEER, permeability assays, tight-junction protein expression, transepidermal water loss models, histology, or protein localization.

Do not use barrier integrity as a vague wellness phrase. A peptide article should say what was measured and where: keratinocyte monolayer, reconstructed epidermis, animal skin, ex vivo tissue, or another model. Tight-junction expression supports barrier context, but it is not the same as a full skin barrier outcome.

Tight junctions#

Tight junctions are protein complexes that help regulate passage between epithelial cells. In skin research, claudins, occludin, and ZO proteins can appear in barrier studies. LL-37 content may mention these markers when the literature supports keratinocyte barrier context.

A tight-junction marker is a piece of evidence, not a full conclusion. The article should ask whether expression, localization, and function were measured. Higher expression without functional permeability data should be described cautiously.

Melanogenesis#

Melanogenesis is the production of melanin by melanocytes. It involves alpha-MSH/MC1R signalling, cAMP pathways, MITF, tyrosinase, melanosome maturation, eumelanin/pheomelanin balance, and transfer to keratinocytes. Melanotan-1 and Melanotan-2 content often sits here.

Melanogenesis is not tanning advice. It is a cellular and pigment-biology term. A study might measure tyrosinase activity, melanin content, MC1R signalling, MITF expression, cell viability, or melanosome transfer. Those endpoints can inform research design, not personal use.

Melanosome transfer#

Melanosome transfer is the movement of melanin-containing organelles from melanocytes to keratinocytes. It is relevant to pigmentation distribution, UV-response biology, and skin photobiology. Northern Compound’s melanosome transfer peptides page handles that deep dive.

If an article discusses melanosome transfer, it should distinguish melanin synthesis from transfer and distribution. A compound can affect one layer without proving the other. This is especially important when comparing Melanotan-1, Melanotan-2, and inflammatory or barrier-context compounds that are not melanocortin tools by default.

Antimicrobial peptide#

An antimicrobial peptide is a peptide that can participate in host defence against microbes. LL-37 is the main skin-archive example. Antimicrobial peptide language can include direct antimicrobial assays, immune modulation, barrier response, chemotaxis, biofilm context, and epithelial signalling.

The phrase is compliance-sensitive. Antimicrobial activity in vitro is not treatment of infection. A supplier page should not imply that a research peptide prevents, treats, or cures microbial disease. Use assay language and model context.

Cytokine panel#

A cytokine panel measures signalling proteins involved in immune and inflammatory response. Skin articles may mention IL-1, IL-6, IL-8, TNF-alpha, IL-10, TGF-beta, chemokines, and related markers. KPV, LL-37, GHK-Cu, and skin-senescence topics can all intersect with cytokine language.

Cytokine results are highly context-dependent. The same cytokine can have different roles depending on timing, tissue, injury state, cell type, and concentration. A cytokine shift does not automatically mean an anti-inflammatory therapeutic effect. It means the model showed a signalling change that needs interpretation.

Senescence-associated secretory phenotype#

The senescence-associated secretory phenotype, or SASP, describes cytokines, chemokines, proteases, and growth factors secreted by senescent cells. In skin, SASP language appears in photoaging, fibroblast senescence, matrix decline, inflammation, and dermal remodelling content. It is relevant to dermal fibroblast senescence peptides.

Do not turn SASP language into anti-aging treatment claims. A study may measure p16, p21, SA-beta-gal, cytokines, MMPs, DNA-damage markers, or cell-cycle arrest. Those are model endpoints. They do not prove visible rejuvenation.

Photoaging model#

A photoaging model studies UV or light-associated skin stress, often through oxidative stress, collagen degradation, MMP induction, inflammation, pigment response, or barrier changes. Photoaging language is common in skin content, but it is easy to overstate because readers associate it with cosmetic outcomes.

A strong article names the exposure model, dose, time course, cell/tissue system, markers, and controls. It avoids advice about sun exposure, tanning, prevention, or treatment. Photobiology is a research field, not a usage instruction.

Assay and documentation glossary#

HPLC purity#

High-performance liquid chromatography, or HPLC, is commonly used to estimate peptide purity by separating components in a sample. In a supplier COA, HPLC purity can show the percentage of the main peak under the stated method. It does not prove identity by itself.

For skin peptides, HPLC purity should be paired with identity confirmation, batch number, fill amount, and storage guidance. A high purity number on a generic COA is weaker than a lot-matched COA with method detail and mass confirmation.

Mass confirmation#

Mass confirmation, often by mass spectrometry, helps verify that the supplied material matches the expected molecular mass. It is especially important when similar names, analogues, salts, complexes, or cosmetic terms can blur identity. GHK-Cu, free GHK, Melanotan-1, Melanotan-2, LL-37, and KPV should not be treated as interchangeable labels.

Mass confirmation does not prove biological performance. It supports identity. The protocol still needs model design, controls, and endpoint interpretation.

Lot-matched COA#

A lot-matched certificate of analysis is a COA tied to the specific batch being evaluated or shipped. It is better than a sample COA because it connects the documentation to the actual material. For Canadian RUO sourcing, the batch number on the product, label, invoice, and COA should line up.

If a supplier cannot provide a lot-specific COA, the buyer has a documentation gap. That gap is especially risky in skin research because compound identity, storage, and purity can change endpoint interpretation.

Storage sensitivity#

Storage sensitivity refers to how heat, light, moisture, oxidation, freeze-thaw cycles, and handling can affect a material. Skin peptide articles should mention storage only as a documentation and research-integrity topic, not as personal-use instruction.

A credible supplier page should state storage expectations for unopened material and, where relevant, research handling constraints. If storage language is missing or generic, record that as a supplier-screening issue. Pair this glossary with the peptide storage and vial inspection checklist for the practical audit trail.

Vial inspection#

Vial inspection means recording label consistency, batch number, fill amount, physical condition, stopper integrity, visible contamination, cake appearance where applicable, and packaging condition. It is not a quality-control substitute for analytical testing, but it catches obvious documentation and handling problems.

For skin peptide materials, vial inspection is useful because visible-outcome categories often attract low-documentation suppliers. A lab file should document what arrived before interpreting any endpoint.

Common misuse patterns to avoid#

“Collagen peptide” as a shortcut#

In consumer language, “collagen peptide” often means dietary collagen fragments or cosmetic positioning. In RUO skin content, that phrase can confuse readers if the article is really about GHK-Cu, fibroblast signalling, collagen expression, or ECM remodelling. Use the exact compound name and endpoint instead.

Bad: “GHK-Cu is a collagen peptide for younger-looking skin.” Better: “GHK-Cu is discussed in dermal matrix research where fibroblast behaviour, collagen markers, MMP/TIMP balance, and wound-context remodelling may be measured.”

“Tanning peptide” as a product label#

“Tanning peptide” is a high-risk consumer phrase. It collapses melanocortin receptor biology into personal-use implication. Northern Compound can acknowledge that people search this way, but the editorial move should be to translate the term into melanocortin and melanogenesis research.

Bad: “Melanotan-2 is a tanning peptide.” Better: “Melanotan-2 is discussed in melanocortin receptor research and should be framed around receptor context, melanocyte endpoints, and RUO documentation rather than tanning use.”

“Wound healing” without model boundaries#

Wound healing is a broad biological process involving inflammation, migration, proliferation, angiogenesis, matrix deposition, remodelling, innervation, microbial context, and mechanical forces. A cell migration assay or cytokine panel can be wound-adjacent without proving wound healing.

Use wound language only when the model supports it. Otherwise say “wound-context model,” “keratinocyte migration,” “fibroblast migration,” “matrix remodelling,” or “re-epithelialization marker.”

“Anti-inflammatory” without a cytokine or pathway#

Anti-inflammatory language can quickly become therapeutic. Safer wording names the measured layer: cytokine panel, NF-kB context, macrophage marker, keratinocyte response, mast-cell degranulation model, or epithelial stress marker. If the article cannot name the layer, it should not use the term.

“Anti-aging” without specifying biology#

Anti-aging is too broad and too consumer-loaded for RUO skin content unless it is clearly describing a search category or article archive. When the real topic is senescence, matrix decline, oxidative stress, photoaging models, or barrier dysfunction, use those terms instead. They are more accurate and less risky.

Canadian RUO sourcing checklist for skin peptide pages#

Use this checklist before linking a skin peptide supplier page from Northern Compound content:

1. Exact identity. Does the page clearly identify GHK-Cu, LL-37, KPV, Melanotan-1, Melanotan-2, or another material without vague cosmetic naming?
2. Lot-matched COA. Does the COA match the batch being offered or shipped?
3. Analytical methods. Does the COA include HPLC purity and mass confirmation where appropriate?
4. Fill amount and format. Does the listing state vial amount, salt or complex where relevant, and material format?
5. Storage guidance. Does the supplier give research-material storage guidance without drifting into personal-use preparation advice?
6. RUO boundary. Does the page avoid treatment, wound-care, tanning, injection, cosmetic-result, anti-aging, scar, acne, infection, or disease claims?
7. Documentation consistency. Do product name, label, invoice, batch number, and COA agree?
8. Endpoint match. Does the product route match the research question, or is it being added because the article needs a commercial link?

The last item is the taste filter. Product links should help readers inspect relevant documentation. They should not be sprinkled into a glossary to make it feel commercial. When in doubt, link to the broader skin peptide supplier checklist or supplier scorecard rather than forcing a compound.

Skin peptide term-to-product map#

Editorial rules for future skin content#

1. Use exact cell types. Write keratinocyte, fibroblast, melanocyte, endothelial cell, immune cell, sebocyte, or hair-follicle cell when that is what the evidence shows.
2. Use exact endpoints. Write TEER, collagen I, MMP/TIMP, melanin content, tyrosinase activity, cytokine panel, scratch assay, or histology when possible.
3. Separate mechanism from outcome. Mechanistic markers support hypotheses. They do not automatically prove visible results or clinical benefits.
4. Avoid consumer instructions. No dosing, injection, topical application, tanning use, wound-care advice, disease management, or personal-use procurement framing.
5. Prefer documentation links over hype. ProductLink routes should help readers inspect live documentation. Internal checklist links should handle COA, storage, and RUO compliance.
6. State the boundary when the term is risky. Words like anti-aging, wound healing, antimicrobial, tanning, and anti-inflammatory need extra context or replacement with assay language.

FAQ#

References and further reading#

• Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm you.
• Pickart L, et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.
• Review. The potential of GHK as an anti-aging peptide.
• Review. The Role of Extracellular Matrix in Skin Wound Healing.
• Study. The Human Cathelicidin LL-37 Host Defense Peptide Upregulates Tight Junction-Related Proteins in Human Keratinocytes.
• Study. Defining MC1R Regulation in Human Melanocytes by Its Agonist alpha-MSH.

This glossary should be updated when Northern Compound adds new skin archive pages, new live product routes, or stronger documentation assets. The standard stays the same: endpoint first, COA first, RUO only.